CJC-1295 + Ipamorelin Stack: The Complete HGH Protocol
Category: Growth Hormone | Reading time: 18 min | Evidence level: Human pharmacokinetic data + established clinical practice
The CJC-1295 + Ipamorelin stack is the most widely used growth hormone peptide protocol in clinical and research settings today. It has largely displaced older GHRH monotherapy and first-generation GHRP compounds for one simple reason: it works through two completely different receptor pathways simultaneously, producing a synergistic GH pulse that neither compound can replicate alone.
This guide covers the full protocol — why these two peptides are combined, which versions to use, every major dosing schedule in clinical circulation, injection timing principles, full cycle structure, what to expect across a cycle timeline, how to manage side effects, sourcing considerations, and a complete cost breakdown. It also includes a direct comparison to standalone use of each peptide, so you can evaluate whether the stack genuinely justifies its complexity.
Research Notice: This content is for educational and research purposes only. CJC-1295 and Ipamorelin are not FDA-approved for human therapeutic use. Any administration in humans requires physician oversight and appropriate laboratory monitoring. Nothing here constitutes medical advice.
Why These Two Peptides Are Combined
The Two-Pathway Architecture of GH Release
The pituitary gland releases growth hormone through two distinct receptor systems:
-
The GHRH receptor — activated by growth hormone-releasing hormone (GHRH) from the hypothalamus. This pathway drives GH synthesis and release through the cAMP-protein kinase A signaling cascade.
-
The GHS-R1a receptor (ghrelin receptor) — activated by ghrelin and synthetic ghrelin mimetics (GHRPs). This pathway drives GH release through intracellular calcium mobilization and IP3 signaling.
These two pathways are mechanistically independent. Activating both simultaneously creates a synergistic effect — the combined GH pulse is not simply additive (1+1=2) but multiplicative (1+1=5 to 10).
This is the core pharmacological rationale for the CJC-1295 + Ipamorelin stack.
What Each Peptide Contributes
CJC-1295 (without DAC / Mod GRF 1-29):
- Binds and activates the GHRH receptor on pituitary somatotrophs
- Drives GH synthesis — it doesn’t just release stored GH, it stimulates the pituitary to produce more
- Extends the amplitude and duration of the GH pulse
- Half-life: ~30 minutes (produces a clean, pulsatile release pattern consistent with physiological GH)
Ipamorelin:
- Binds and activates GHS-R1a, the ghrelin receptor, via a completely separate pathway
- Amplifies the GH pulse amplitude through intracellular calcium mobilization
- Provides the cleanest GHRP profile available — no meaningful cortisol, prolactin, or appetite stimulation at standard doses
- Half-life: ~2 hours (sustains the post-injection GH elevation longer than CJC-1295 alone)
When co-administered, CJC-1295 primes the pituitary (increased GH synthesis, GHRH receptor activation) while Ipamorelin independently triggers GH exocytosis through ghrelin pathway signaling. The result is a GH pulse that animal studies suggest is 5–10× greater than either compound alone — a finding consistent with the mechanistic synergy and with reported clinical outcomes.
Why Ipamorelin Specifically (Not GHRP-2 or GHRP-6)
Ipamorelin is the preferred GHRP partner for CJC-1295 in modern protocols for a specific, evidence-based reason: receptor selectivity.
Older GHRPs produce similar GH stimulation but with significant off-target effects:
- GHRP-6: Produces a large GH pulse but causes ~100% cortisol elevation and substantial appetite stimulation (via ghrelin cross-reactivity in the hypothalamus)
- GHRP-2: More potent than GHRP-6 for GH, but elevates cortisol ~100% and prolactin ~50% above baseline
Ipamorelin, by contrast, elevates GH with only ~5% cortisol and prolactin change — not statistically significant in human pharmacokinetic studies (Raun et al., 1998). When managing a long-term protocol where cortisol management matters — for recovery, sleep quality, and body composition — Ipamorelin’s cleaner profile makes it the rational choice.
Which Version of CJC-1295 to Use
This is the most common source of confusion when researching this stack.
CJC-1295 exists in two distinct forms:
| CJC-1295 without DAC (Mod GRF 1-29) | CJC-1295 with DAC | |
|---|---|---|
| Half-life | ~30 minutes | ~6–8 days |
| GH release pattern | Pulsatile (physiological) | Sustained “GH bleed” |
| Dosing frequency | 1–3× daily | Once weekly |
| Used in stack? | Yes — standard choice | Rarely; not recommended for most |
| IGF-1 pattern | Pulsatile elevation | Sustained chronic elevation |
The clinical standard for the CJC-1295 + Ipamorelin stack is always the without-DAC version.
The DAC version’s 6–8 day half-life produces continuous, non-pulsatile GH elevation. This is pharmacologically distinct from how the body naturally regulates GH — the physiological pattern is pulsatile, with discrete peaks separated by periods of low GH. Continuous GH elevation may blunt GH receptor sensitivity over time and produces chronic IGF-1 elevation whose long-term implications are not fully characterized.
The without-DAC version (Mod GRF 1-29) produces a clean ~30-minute pulse, allows somatostatin to perform its normal regulatory function between injections, and preserves the physiological pulsatile architecture. This is why virtually all clinical compounding protocols for this stack use the without-DAC form.
Dosing Schedules
Standard Dosing Range
Both peptides are typically dosed in a 1:1 ratio at the same time:
| Peptide | Low Dose | Standard Dose | High Dose |
|---|---|---|---|
| CJC-1295 (no DAC) | 100 mcg | 200 mcg | 300 mcg |
| Ipamorelin | 100 mcg | 200 mcg | 300 mcg |
Most clinical protocols start at 100–200 mcg of each, combined in a single injection. Dose escalation above 300 mcg per injection does not appear to produce proportional increases in GH release — saturation of receptor response becomes a factor, and the incremental benefit diminishes relative to the increased peptide load.
Many compounding pharmacies provide combination vials (e.g., 200 mcg CJC-1295 / 200 mcg Ipamorelin per vial or per pre-loaded dose), which simplifies preparation and eliminates the need to manage two separate reconstitutions.
Schedule 1: Daily Protocol (1 Injection/Day)
The most widely used entry-level protocol:
Protocol structure:
- 1 injection per day
- Dose: 100–200 mcg CJC-1295 / 100–200 mcg Ipamorelin
- Timing: Before sleep (30–60 minutes prior to bed)
- Days: 7 days/week
Rationale: The largest natural GH pulse of the day occurs 60–90 minutes after sleep onset during slow-wave (deep) sleep. A pre-bed injection amplifies and extends this physiological peak, producing the highest possible GH pulse with minimal disruption to daytime hormonal patterns.
Best for: First-time users, conservative protocols, anti-aging and longevity applications where gentle, consistent GH support is the goal.
Schedule 2: 5-On / 2-Off Protocol
A widely used modification that introduces rest days to reduce potential receptor desensitization:
Protocol structure:
- 1–2 injections per day, Monday through Friday
- 2 complete rest days (typically Saturday and Sunday)
- Dose: 200 mcg of each per injection
Rationale: The 5-on/2-off structure is borrowed from clinical TRT and hormone protocols where scheduled pauses allow receptors to reset and prevent tachyphylaxis (diminishing response with continuous stimulation). Whether this is strictly necessary for GHRPs and GHRH analogs is debated — but the protocol remains common and allows for lifestyle flexibility (e.g., less structured weekends).
Best for: Researchers who prefer structured cycles, those concerned about long-term receptor sensitivity, and protocols running 12+ weeks.
Schedule 3: Twice-Daily Protocol
The highest-frequency standard protocol:
Protocol structure:
- 2 injections per day
- Injection 1: Morning, upon waking (fasted state)
- Injection 2: Before sleep (30–60 minutes pre-bed)
- Dose: 100–200 mcg of each per injection
Rationale: Adding a morning injection to the standard pre-bed timing creates two daily GH pulses — one capitalizing on the natural nocturnal GH surge, one exploiting the morning fasted state when GH secretion is otherwise relatively low but the pituitary is responsive. This produces higher mean GH and IGF-1 over 24 hours, which theoretically translates to enhanced anabolic, lipolytic, and tissue-repair effects.
Fasting requirement applies to both injections: Blood glucose and circulating insulin suppress GH secretion. Both morning and evening injections should be separated from meals by at least 2–3 hours to avoid blunting the GH response. The morning injection is administered immediately upon waking, before breakfast. The evening injection is administered 2–3 hours after the last meal of the day.
Best for: Body composition goals (muscle gain, fat loss), recovery optimization, and those who have established baseline tolerance on the once-daily protocol.
Schedule 4: Three-Times-Daily Protocol
Less commonly used but referenced in some aggressive clinical protocols:
Protocol structure:
- 3 injections per day (morning fasted, midday fasted 2–3 hours post-lunch, pre-bed)
- Dose: 100 mcg of each per injection
- Total daily: 300 mcg CJC-1295 / 300 mcg Ipamorelin
Note: The practical constraint on three-daily dosing is the fasting requirement — a midday injection requires a 2–3 hour gap from both breakfast and lunch, which is difficult to maintain in most schedules. For this reason, the twice-daily protocol is generally preferred over a three-times-daily structure.
Injection Timing: The Rules That Matter
Fasting State Is Non-Negotiable
Elevated blood glucose and insulin directly suppress pituitary GH secretion. This is a physiological fact, not a minor optimization:
- Eating within 2 hours of injection significantly blunts the GH pulse amplitude
- High-carbohydrate meals are more suppressive than protein or fat meals
- The morning fasted state (12+ hours since last meal) is ideal timing for a second injection
Practical guideline: Never inject within 2 hours of a carbohydrate-containing meal. If meal timing and injection timing conflict, prioritize fasting compliance — a blunted GH pulse from poor timing can negate a significant portion of the peptide’s effect.
Pre-Sleep Timing
For the bedtime injection:
- Administer 30–60 minutes before sleep
- The GH pulse will coincide with the onset of slow-wave sleep (which typically begins 60–90 minutes after sleep onset)
- Avoid high-carbohydrate foods in the 2–3 hours before the injection
- Post-injection snacks should be protein-only if anything
Pre-Workout Timing
A less commonly used but referenced approach for body composition:
- Administer 30–60 minutes before training (fasted or 3+ hours post-meal)
- The GH pulse during exercise may synergize with exercise-induced GH release
- This timing is typically used as an additional injection, not a replacement for the pre-sleep dose
- Less well-studied than sleep timing for GH optimization
Cycle Length
Standard 8–12 Week Cycle
The research and clinical standard for CJC-1295 + Ipamorelin protocols is 8–12 weeks of continuous use, followed by a rest period.
Why 8–12 weeks:
- IGF-1 elevation (the downstream marker most tracked in clinical protocols) takes 4–6 weeks to reach a new steady state in response to enhanced GH pulsatility
- Meaningful body composition changes require IGF-1 elevation to be sustained for at least 6–8 weeks
- The 8-week minimum captures the full IGF-1 response; the 12-week window is the standard for most body composition applications
Cycle Structure with Off Period
| Phase | Duration | Notes |
|---|---|---|
| Introductory period | Weeks 1–2 | Start at lower dose (100 mcg each); assess tolerance |
| Dose escalation | Week 3 | Move to target dose (200 mcg each) if tolerating well |
| Maintenance | Weeks 3–12 | Consistent dosing; monitor IGF-1 at week 4–6 |
| Off period | 4–8 weeks | Allow pituitary receptor sensitivity to reset |
Rest Periods and Cycling Rationale
The GH secretagogue literature suggests receptor sensitivity can diminish with continuous stimulation. An off period of 4–8 weeks between cycles is the clinical convention — though the evidence for exactly how long is needed is not precise. Some researchers and physicians use continuous dosing protocols (especially in anti-aging medicine), citing the preserved pulsatile architecture of the without-DAC combination as sufficient protection against desensitization.
For research purposes, a cycle/off structure is the more conservative approach and allows for meaningful comparison of on-cycle versus off-cycle laboratory values.
Expected Results Timeline
What to expect is highly individual — GH secretagogue response varies substantially based on baseline GH status, age, body composition, pituitary responsiveness, lifestyle factors, and dosing compliance. The timeline below reflects reported outcomes in clinical practice and published literature.
| Timepoint | Commonly Reported Changes |
|---|---|
| Week 1–2 | Improved sleep quality (deeper sleep, more vivid dreams); mild water retention (1–2 lbs); injection site flush or redness |
| Week 2–4 | Reduced recovery time post-training; improved sense of wellbeing; some users report improved skin texture and appearance |
| Week 4–6 | IGF-1 measurably elevated on lab work (1.5–3× baseline typical); first visible changes in body composition in those on structured training/nutrition programs |
| Week 6–8 | More pronounced fat loss effects (particularly visceral and abdominal); muscle preservation during any concurrent caloric restriction; improved joint comfort reported by some |
| Week 8–12 | Peak body composition response for the cycle; some users report continued lean mass accrual; continued improvement in recovery, sleep, and GH-related markers |
| Post-cycle | GH and IGF-1 return toward baseline within 1–2 weeks of stopping; body composition changes are not immediately reversed but require continued training stimulus to maintain |
The Realistic Expectations Caveat
The CJC-1295 + Ipamorelin stack works by optimizing the GH axis, not by replacing pharmaceutical HGH. The GH pulses it generates are larger than your natural baseline but remain within physiological ranges — they are not supraphysiologic in the way that exogenous HGH injections can be.
For healthy adults with near-normal baseline GH function, the incremental benefit is real but modest when measured against rigorous endpoints. For older adults experiencing age-related GH decline (which typically begins in the 30s and accelerates in the 40s–50s), the stack’s impact on restoring a more youthful GH secretory pattern is likely greater and more clinically meaningful.
Side Effects and How to Mitigate Them
Common, Expected Side Effects
Water Retention (Most Common)
- Mechanism: GH elevation promotes sodium and water retention
- Onset: Usually weeks 1–3; often resolves or diminishes with continued use
- Severity: Mild; typically 1–3 lbs of fluid, most noticeable in hands and face
- Mitigation: Reduce carbohydrate intake, increase water consumption, ensure adequate electrolyte balance; if persistent, consider reducing dose
Injection Site Reactions
- Mechanism: Local tissue response to subcutaneous injection
- Common presentation: Mild redness, transient itch, or small welt at injection site
- Mitigation: Rotate injection sites consistently (abdomen, upper thigh, deltoid); allow sites to fully heal before reusing; ensure proper injection technique; refrigerate peptides appropriately
Headache
- Mechanism: Likely related to fluid redistribution from GH elevation
- Common presentation: Mild, transient; more common in the first 1–2 weeks
- Mitigation: Adequate hydration; usually self-resolving; reduce dose if persistent
Tingling or Numbness in Extremities
- Mechanism: GH-mediated fluid retention can create mild compression of peripheral nerves
- Presentation: Typically hands or feet; mild and transient
- Mitigation: Usually resolves within the first month; reduce dose if significant
Facial Flushing Post-Injection
- Mechanism: Transient vasodilation response; common across all GH secretagogues
- Presentation: Brief warmth or redness in face and neck, resolves within 5–15 minutes
- Mitigation: Normal and expected; no action required
Side Effects That Should Prompt Dose Adjustment or Discontinuation
Significant Blood Glucose Elevation
- GH is counter-regulatory to insulin. Elevated GH transiently reduces insulin sensitivity.
- Risk population: Pre-diabetic or insulin-resistant individuals are at higher risk
- Action: Monitor fasting glucose during protocol; if elevated above personal baseline, consult a physician and reduce dose or discontinue
- Context: At standard doses, clinically meaningful glucose elevation is not consistently documented in otherwise healthy individuals — but the mechanism exists and monitoring is appropriate
Persistent, Worsening Edema
- If water retention doesn’t diminish after 3–4 weeks and is affecting quality of life or blood pressure
- Action: Reduce dose by 50% for 1–2 weeks; most cases resolve
IGF-1 Over-Elevation
- Chronic supraphysiologic IGF-1 is a theoretical cancer risk (via mitogenic stimulation)
- The clinical goal is IGF-1 normalization (restoring age-appropriate levels), not maximization
- Action: Test IGF-1 at week 4–6; if levels significantly above age-adjusted normal range, reduce dose or extend off-cycle period
What This Stack Does NOT Cause (Key Differentiators)
| Effect | GHRP-6 | GHRP-2 | CJC-1295 + Ipamorelin |
|---|---|---|---|
| Cortisol elevation | ~100% above baseline | ~100% above baseline | ~5% (not significant) |
| Prolactin elevation | Moderate | ~50% above baseline | ~5% (not significant) |
| Appetite stimulation | Significant | Moderate | Minimal |
| Hypoglycemia | No | No | No |
This table is the primary reason Ipamorelin replaced GHRP-2 and GHRP-6 in clinical protocols. The selectivity profile eliminates the cortisol/prolactin burden that undermined body composition goals in earlier stacks.
Sourcing Considerations
Two Legitimate Channels
Compounding Pharmacies (Prescription Required)
In the United States, CJC-1295 and Ipamorelin can be legally prescribed by a licensed physician and filled at an FDA-registered 503A compounding pharmacy. This is the legally compliant path for human use.
Key characteristics of compounding pharmacy product:
- Pharmaceutical-grade purity testing (COA available)
- Sterile preparation in a compliant facility
- Prescription oversight ensures appropriate dosing and monitoring
- Typically combined in a single vial for convenience
- Requires initial consultation and baseline lab work (typically IGF-1, metabolic panel)
Research Chemical Suppliers (Research Use Only)
For laboratory and in-vitro research purposes, CJC-1295 and Ipamorelin are available from research chemical suppliers. Research-grade peptides are sold for non-human research use and are not legal for human administration outside of clinical research.
Quality considerations when evaluating research suppliers:
- Third-party COA (Certificate of Analysis): HPLC purity testing from an independent lab; target ≥98% purity
- Mass spectrometry verification: Confirms the peptide sequence matches the labeled compound
- Sterility testing: Relevant only for injectable-grade preparations
- Cold chain compliance: Lyophilized peptides require refrigeration; verify storage and shipping protocols
Cost Breakdown Per Cycle
Compounding Pharmacy (Prescription Protocol)
| Item | Estimated Cost |
|---|---|
| Initial consultation and baseline labs (IGF-1, metabolic panel) | $150–$400 |
| Combined CJC-1295 / Ipamorelin (200 mcg/200 mcg per dose, 30-dose vial) | $150–$250/month |
| Mid-cycle IGF-1 monitoring lab | $50–$150 |
| 8-week cycle total | ~$550–$1,100 |
| 12-week cycle total | ~$700–$1,350 |
Note: These are estimated ranges. Compounding pharmacy pricing varies by provider, geographic location, and whether the protocol is part of a supervised anti-aging or hormone clinic program. Clinic programs often bundle consultation, labs, and peptides into a monthly subscription model ($200–$500/month all-in).
Research-Grade Suppliers (Laboratory Research Pricing)
| Item | Estimated Cost |
|---|---|
| CJC-1295 (no DAC) 5 mg vial | $25–$60 per vial |
| Ipamorelin 5 mg vial | $25–$60 per vial |
| Bacteriostatic water | $8–$15 |
| Syringes and needles (100 pack) | $15–$25 |
| 8-week cycle (twice-daily, 200 mcg each) | ~$120–$250 peptide cost |
Total peptide required for common cycles:
| Protocol | Duration | CJC-1295 Total | Ipamorelin Total |
|---|---|---|---|
| Daily, 200 mcg | 8 weeks | 11.2 mg | 11.2 mg |
| Daily, 200 mcg | 12 weeks | 16.8 mg | 16.8 mg |
| Twice-daily, 200 mcg each | 8 weeks | 22.4 mg | 22.4 mg |
| Twice-daily, 200 mcg each | 12 weeks | 33.6 mg | 33.6 mg |
Standalone vs. Stack: Does the Combination Justify the Complexity?
CJC-1295 Alone
GH response: 3–5× baseline
Protocol: 1–3 injections/day, fasted
Cortisol/prolactin: No meaningful elevation
Missing: No ghrelin pathway stimulation; GH pulse amplitude limited to GHRH receptor response only
Ipamorelin Alone
GH response: 2–4× baseline
Protocol: 1–3 injections/day
Cortisol/prolactin: ~5% elevation (minimal)
Missing: No GHRH receptor stimulation; somatostatin’s inhibitory effect is not counteracted as effectively; lower total GH pulse amplitude
CJC-1295 + Ipamorelin Stack
GH response: Estimated 5–10× baseline (synergistic, not additive)
Protocol: Same injection count, same timing — two peptides in one injection
Cortisol/prolactin: Minimal (Ipamorelin’s clean profile maintained)
Advantage: Dual-pathway stimulation; maximum GH amplitude within physiological range; no added injection burden (same frequency, combined vial)
The Stack Conclusion
The combination genuinely earns its status as the clinical standard. The operational complexity is minimal — combination vials mean no additional injections versus monotherapy. The pharmacological payoff — a GH pulse 5–10× larger than baseline vs. 2–5× with either alone — is substantive and grounded in the established mechanism.
The only scenario where monotherapy makes sense over the stack is specific cost constraints, or protocols where simplicity is prioritized over potency (e.g., initial trial periods, or Sermorelin being used as a gentler entry point before escalating to the full stack).
Pre-Cycle Checklist
Before beginning a CJC-1295 + Ipamorelin protocol, the following is the responsible research preparation checklist:
- Baseline IGF-1 test — establishes your pre-cycle IGF-1 level; required for monitoring and ensuring you’re not starting with already-elevated levels
- Fasting glucose and HbA1c — baseline metabolic markers relevant to GH’s insulin-opposing effects
- Physician consultation — essential for legal prescriptions; strongly recommended even for research use given the metabolic monitoring requirements
- Peptide quality verification — COA confirming purity ≥98% and mass spec peptide sequence verification
- Reconstitution supplies — bacteriostatic water, insulin syringes (29–31 gauge, 0.5 mL), alcohol swabs, sharps container
- Injection site rotation plan — 3–4 rotation sites to prevent tissue desensitization
Monitoring During the Cycle
Week 4–6 bloodwork (recommended):
- IGF-1 — primary efficacy marker; target is restoration to upper-normal age range, not maximization
- Fasting glucose — check for GH-mediated insulin resistance
- Blood pressure — water retention can modestly affect BP in sensitive individuals
Signs the protocol is working:
- IGF-1 elevation on lab work
- Improved sleep architecture (deeper sleep, more restorative)
- Reduced DOMS (delayed onset muscle soreness)
- Gradual improvement in body composition with structured training/nutrition
Protocol Library CTA
Get the full optimized protocol inside the library.
The HelixVault Protocol Library contains complete, downloadable CJC-1295 + Ipamorelin cycle guides — including week-by-week dosing schedules, lab monitoring timelines, reconstitution calculators, injection site rotation maps, and clinical reference data. Everything organized in one place, updated as new research emerges.
Summary
The CJC-1295 + Ipamorelin stack is the most evidence-informed growth hormone peptide protocol currently available outside of pharmaceutical HGH. Its scientific foundation — dual-pathway synergistic GH stimulation — is mechanistically sound and supported by human pharmacokinetic data for both component peptides.
The key protocol decisions in summary:
- Version: CJC-1295 without DAC (Mod GRF 1-29) — always, not the DAC form
- Dose: 200 mcg of each per injection; start at 100 mcg for the first 1–2 weeks
- Frequency: Once daily (conservative) or twice daily (body composition focus)
- Timing: Pre-sleep primary; add morning fasted injection for twice-daily protocols
- Fasting compliance: 2–3 hours post-meal minimum; non-negotiable for GH pulse optimization
- Cycle length: 8–12 weeks; followed by 4–8 week off period
- Monitoring: Baseline and mid-cycle IGF-1, fasting glucose
- Sourcing: Compounding pharmacy (prescription) for human use; research suppliers for laboratory applications
The stack’s clinical dominance is justified: same injection burden as monotherapy, but the dual-pathway mechanism produces a GH response that neither peptide achieves alone.
This article is for research and informational purposes only. HelixVault does not sell peptides or other compounds. All content reflects publicly available scientific literature and reported clinical practice. Consult a licensed healthcare provider before initiating any peptide therapy. CJC-1295 and Ipamorelin are not approved by the FDA for human therapeutic use.
Sources: Raun K, et al. “Ipamorelin, the first selective growth hormone secretagogue.” Eur J Endocrinol. 1998;139(5):552-561. Alba M, et al. “Once-monthly administration of CJC-1295.” J Clin Endocrinol Metab. 2006;91(8):2953-2960. Bowers CY. “History of the development of GHRPs.” 2013.
Found this useful? Share it with someone who'd benefit.